VYNE Therapeutics schedules special cash dividend payments contingent on Yarrow Bioscience merger.

Record date for the special cash dividend is July 22, 2026, with the dividend payable to stockholders and warrant holders of record on that date; the dividend payment date is July 23, 2026, and the merger closing is expected on or about July 24, 2026.
The estimated per-share dividend is based on 42,989,506 shares of common stock and common stock equivalents outstanding as of July 9, 2026.
The aggregate cash dividend amount and the per-share amount are not disclosed in the releases; final figures will be calculated under the Merger Agreement, and are subject to the Merger Agreement calculations.
Payment is conditioned on the closing of the merger with Yarrow Bioscience, and stockholders will vote on the merger at a special meeting; closing timing is contingent on approvals and conditions under the Merger Agreement.
The transfer agent will distribute the cash dividend to stockholders and warrant holders within a few days following the Dividend Payment Date.
VYNE Therapeutics has declared a special cash dividend of approximately $16.5 million, or about $0.38 per share, tied to its planned merger with Yarrow Bioscience, according to TipRanks and Investing.com. The dividend will be paid to stockholders and warrant holders of record on July 22, 2026, with payment set for July 23 — just one day before the merger is expected to close.
The payout is not guaranteed. VYNE has made clear the dividend depends entirely on the merger closing as planned. Stockholders must first approve the deal at a special meeting before any cash changes hands.
VYNE has laid out a tight three-day sequence. The record date is July 22, 2026. The dividend pays out on July 23. The merger with Yarrow Bioscience is expected to close on or about July 24, according to MarketScreener. Miss any one of those steps, and the dividend does not go out.
The per-share estimate of $0.38 is based on 42,989,506 shares of common stock and common stock equivalents outstanding as of July 9, 2026, according to GuruFocus. The transfer agent will distribute the cash within a few days after the payment date.
The dividend stems from a December 17, 2025 Agreement and Plan of Merger and Reorganization between VYNE and Yarrow Bioscience, according to TipRanks. That deal set the terms for how VYNE's net cash would be distributed before the company reorganizes under the merger structure.
The exact aggregate dividend amount and the final per-share figure are still subject to calculations under the Merger Agreement, according to Goldea Capital. The $16.5 million and $0.38 figures are estimates, not locked-in numbers.
Before any dividend reaches investors, stockholders must vote to approve the merger at a special meeting. VYNE has not announced a specific date for that vote. The merger closing — and by extension the dividend — hinges on that approval and other conditions spelled out in the Merger Agreement.
VYNE has been direct about the risk. The company says the dividend is not guaranteed until the merger actually closes. If the deal falls apart, stockholders get nothing from this payout, according to Investing.com.
For shareholders, $0.38 per share in cash is a concrete near-term return tied to a transaction that reshapes the company. VYNE trades on Nasdaq under the ticker VYNE. The stock had roughly 43 million shares outstanding as of early July 2026, according to GuruFocus.
Warrant holders are also included in the dividend. They must be holders of record on July 22 to qualify. The transfer agent handles distribution, with cash expected to arrive within days of the July 23 payment date, according to Goldea Capital.
Publishers
10
Articles
21
Reach
31